ストックスクリーナーアプリを入手
33.43
2.92%
0.95
前日終値:
$32.48
開ける：
$32.47
24時間の取引高:
548.99K
Relative Volume:
0.91
時価総額：
$1.87B
収益：
$651.97M
当期純損益:
$59.71M
株価収益率:
31.25
EPS:
1.0696
ネットキャッシュフロー:
$172.03M
1週間 パフォーマンス:
+5.46%
1か月 パフォーマンス:
+8.86%
6か月 パフォーマンス:
-6.02%
1年 パフォーマンス:
+14.64%
1日の値動き範囲:
$32.34
$33.74
1週間の範囲:
$31.38
$33.74
52週間の値動き範囲:
$25.53
$40.28
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
名前
Supernus Pharmaceuticals Inc
セクター
電話
301-838-2500
住所
9715 KEY WEST AVENUE, ROCKVILLE, MD
SUPN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
33.43 | 1.77B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
HLN
Haleon Plc Adr
|
10.80 | 48.39B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
163.04 | 70.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.85 | 3.54M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.11 | 45.20B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.94 | 19.42B | 16.54B | -1.64B | 749.00M | -1.45 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-19 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-09-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | 再開されました | Jefferies | Buy |
| 2021-12-01 | 再開されました | Jefferies | Buy |
| 2021-04-13 | アップグレード | Jefferies | Hold → Buy |
| 2020-06-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | 再開されました | Jefferies | Hold |
| 2019-11-08 | ダウングレード | Berenberg | Buy → Hold |
| 2019-11-07 | ダウングレード | Stifel | Buy → Hold |
| 2019-11-06 | ダウングレード | Jefferies | Buy → Hold |
| 2018-11-12 | 繰り返されました | B. Riley FBR | Buy |
| 2018-01-18 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | アップグレード | Janney | Neutral → Buy |
| 2017-11-08 | アップグレード | Stifel | Hold → Buy |
| 2017-10-19 | 開始されました | FBR & Co. | Buy |
| 2017-09-19 | ダウングレード | Stifel | Buy → Hold |
| 2017-07-17 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | 開始されました | Janney | Neutral |
| 2017-06-01 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | アップグレード | Jefferies | Hold → Buy |
| 2015-11-05 | 繰り返されました | Northland Capital | Outperform |
| 2015-10-28 | 開始されました | Northland Capital | Outperform |
すべてを表示
Supernus Pharmaceuticals Inc (SUPN) 最新ニュース
The Manufacturers Life Insurance Company Sells 797 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock? - Nasdaq
Solid Earnings Reflect Supernus Pharmaceuticals' (NASDAQ:SUPN) Strength As A Business - Yahoo Finance
Supernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on Wednesday - Defense World
SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Supernus Pharmaceuticals, Inc. investment - ACCESS Newswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com - Defense World
Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Stock Surge: Supernus Pharmaceuticals Inc (SUPN) Closes at 30.94, Marking a -4.59 Increase/Decrease - DWinneX
Levi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsSUPN - ACCESS Newswire
Supernus Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by First Trust Advisors LP - Defense World
SUPN STOCK ALERT: Levi & Korsinsky Notifies Supernus Pharmaceuticals, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Earnings call transcript: Supernus Q1 2025 earnings miss expectations By Investing.com - Investing.com Canada
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Supernus: Q1 Earnings Snapshot - CTPost
Earnings call transcript: Supernus Q1 2025 earnings miss expectations - Investing.com
Supernus Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Est - GuruFocus
SUPN Reports Higher than Expected Q1 Revenue at $149.8M | SUPN S - GuruFocus
Supernus Announces First Quarter 2025 Financial Results | SUPN S - GuruFocus
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Supernus Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
SUPERNUS PHARMACEUTICALS Earnings Results: $SUPN Reports Quarterly Earnings - Nasdaq
Earnings Flash (SUPN) Supernus Pharmaceuticals Q1 Loss Per Share $0.21 Vs. FactSet Est. Loss $0.01 - marketscreener.com
Supernus Announces First Quarter 2025 Financial Results | SUPN Stock News - GuruFocus
Supernus Announces First Quarter 2025 Financial Results - GlobeNewswire
Investors who Lost Money on Supernus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationSUPN - ACCESS Newswire
Uncovering Potential: Supernus Pharmaceuticals's Earnings Preview - Nasdaq
Supernus Pharmaceuticals, Inc. (SUPN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - Louisiana First News
Supernus Pharmaceuticals Earnings: What To Look For From SUPN - Yahoo Finance
How To Trade (SUPN) - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
Supernus: New Direction Beckons After MDD Drug Fail (Rating Downgrade) (NASDAQ:SUPN) - Seeking Alpha
BlackRock, Inc. Reduces Stake in Supernus Pharmaceuticals Inc - GuruFocus
Supernus Pharmaceuticals (NASDAQ:SUPN) investors are up 6.5% in the past week, but earnings have declined over the last five years - simplywall.st
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals - The Globe and Mail
What Makes Supernus (SUPN) a New Buy Stock - Yahoo Finance
Investor Network: Supernus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Envestnet Asset Management Inc. Has $2.17 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
LPL Financial LLC Increases Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Wells Fargo & Company MN Boosts Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Bank of Montreal Can Buys 473 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals Inc (SUPN) 財務データ
収益
当期純利益
現金流量
EPS
Supernus Pharmaceuticals Inc (SUPN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| DEC TIMOTHY C | Senior Vice-President & CFO |
Mar 10 '25 |
Option Exercise |
0.00 |
3,800 |
0 |
13,636 |
| Khattar Jack A. | President, CEO |
Mar 07 '25 |
Option Exercise |
0.00 |
38,640 |
0 |
992,219 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
Mar 07 '25 |
Option Exercise |
0.00 |
2,625 |
0 |
16,507 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
Feb 26 '25 |
Option Exercise |
0.00 |
5,760 |
0 |
17,683 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 21 '25 |
Option Exercise |
0.00 |
1,650 |
0 |
11,799 |
| Rubin Jonathan | SVP, Chief Medical Officer |
Feb 21 '25 |
Option Exercise |
0.00 |
1,875 |
0 |
8,780 |
| Rubin Jonathan | SVP, Chief Medical Officer |
Feb 21 '25 |
Sale |
39.15 |
927 |
36,292 |
7,853 |
| Mottola Frank | SVP, Quality, GMP, Ops, IT |
Feb 21 '25 |
Option Exercise |
0.00 |
1,125 |
0 |
9,576 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Option Exercise |
29.61 |
9,477 |
280,614 |
19,626 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Feb 04 '25 |
Sale |
39.70 |
9,477 |
376,237 |
10,149 |
0.57%
大文字化:
|
ボリューム (24 時間):